Home
/
Spero Therapeutics, Inc.
/
Financials
/
Quarterly
Spero Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Spero Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$5.44M
Nov 13, 2025
Q2
2025
Jun 30, 2025
$14.19M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$5.87M
May 13, 2025
Q3
2025
Sep 30, 2024
$13.47M
Nov 13, 2025
Q2
2025
Jun 30, 2024
$10.20M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$9.27M
May 13, 2025
Q3
2024
Sep 30, 2023
$25.47M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$2.72M
Aug 5, 2024
Q1
2024
Mar 31, 2023
$2.07M
May 15, 2024
Q3
2023
Sep 30, 2022
$2.01M
Nov 13, 2023
Q2
2023
Jun 30, 2022
$1.99M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$2.07M
May 11, 2023
Q3
2022
Sep 30, 2021
$3.06M
Nov 14, 2022
Q2
2022
Jun 30, 2021
$5.15M
Aug 10, 2022
Q1
2022
Mar 31, 2021
$7.30M
May 16, 2022
Q3
2021
Sep 30, 2020
$4.00M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$1.73M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$1.70M
May 6, 2021
Q3
2020
Sep 30, 2019
$4.64M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$2.16M
Aug 6, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 13, 2025
Q2
2025
Jun 30, 2025
$0
Aug 12, 2025
Q1
2025
Mar 31, 2025
$12.0K
May 13, 2025
Q3
2025
Sep 30, 2024
$65.0K
Nov 13, 2025
Q2
2025
Jun 30, 2024
$114.0K
Aug 12, 2025
Q1
2025
Mar 31, 2024
$140.0K
May 13, 2025
Q3
2024
Sep 30, 2023
$218.0K
Nov 14, 2024
Q2
2024
Jun 30, 2023
$269.0K
Aug 5, 2024
Q1
2024
Mar 31, 2023
$223.0K
May 15, 2024
Q3
2023
Sep 30, 2022
$1.08M
Nov 13, 2023
Q2
2023
Jun 30, 2022
$896.0K
Aug 10, 2023
Q1
2023
Mar 31, 2022
$247.0K
May 11, 2023
Q3
2022
Sep 30, 2021
$708.0K
Nov 14, 2022
Q2
2022
Jun 30, 2021
$2.11M
Aug 10, 2022
Q3
2021
Sep 30, 2020
$38.0K
Nov 10, 2021
Q2
2021
Jun 30, 2020
$51.0K
Aug 5, 2021
Q1
2021
Mar 31, 2020
$169.0K
May 6, 2021
Q3
2020
Sep 30, 2019
$172.0K
Nov 5, 2020
Q2
2020
Jun 30, 2019
$67.0K
Aug 6, 2020
Q1
2020
Mar 31, 2019
$3.81M
May 8, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.38M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($1.70M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($13.87M)
May 13, 2025
Q3
2025
Sep 30, 2024
($17.15M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($17.86M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($12.67M)
May 13, 2025
Q3
2023
Sep 30, 2023
($3.20M)
Nov 13, 2023
Q2
2024
Jun 30, 2023
($11.90M)
Aug 5, 2024
Q1
2024
Mar 31, 2023
($13.30M)
May 15, 2024
Q3
2023
Sep 30, 2022
($11.70M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($28.70M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($32.80M)
May 11, 2023
Q3
2022
Sep 30, 2021
($22.50M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($18.60M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
($19.40M)
May 16, 2022
Q3
2021
Sep 30, 2020
($18.90M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($17.50M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($23.30M)
May 6, 2021
Q3
2020
Sep 30, 2019
($17.70M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($13.20M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.92M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($2.44M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($14.73M)
May 13, 2025
Q3
2025
Sep 30, 2024
($18.59M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($19.06M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($13.98M)
May 13, 2025
Q3
2024
Sep 30, 2023
($1.93M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($12.89M)
Aug 5, 2024
Q1
2024
Mar 31, 2023
($14.23M)
May 15, 2024
Q3
2023
Sep 30, 2022
($11.83M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($26.08M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($30.21M)
May 11, 2023
Q3
2022
Sep 30, 2021
($22.52M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($18.54M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
($19.40M)
May 16, 2022
Q3
2021
Sep 30, 2020
($19.02M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($18.48M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($22.82M)
May 6, 2021
Q3
2020
Sep 30, 2019
($17.99M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($13.65M)
Aug 6, 2020